- Founded
- 2021
- Stage
- Series A
- Invested
- 2022
- Status
- Acquired by AstraZeneca
Developer of breakthrough biotherapeutics for B cell cancers, metabolic diseases, and chronic hepatitis B infections
Ben Buelow, MD, PhD (Co-founder), Roland Buelow, PhD (Co-founder), Wim Van Schooten, PhD (Co-founder)